Division of Nephrology and Hypertension, Medicine Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania.
Division of Nephrology and Hypertension, Medicine Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania.
Transplant Proc. 2021 Apr;53(3):885-888. doi: 10.1016/j.transproceed.2020.06.042. Epub 2020 Sep 24.
Transplantation of African American (AA) compared to non-AA donor kidneys is generally associated with inferior outcomes. It is unclear whether enhanced genetic risk associated with AA donor kidneys would be counterbalanced by favorable immunologic matching when AA donor kidneys are transplanted into AA recipients. We aimed to compare the outcomes of AA vs non-AA deceased-donor kidneys (DDKs) stratified by kidney donor profile index (KDPI) that were transplanted into AA recipients.
Using the Organ Procurement and Transplant Network/United Network for Organ Sharing database, we identified AA DDK recipients from 2000 to 2015 who received peri-operative induction followed by calcineurin inhibitor/mycophenolate mofetil maintenance. These patients were divided into 4 KDPI groups (0%-20%, 21%-50%, 51%-85%, and 86%-100%). Adjusted long-term graft and patient outcomes were compared between AA recipients of kidneys from AA vs non-AA donors in each KDPI category using a multivariable Cox model.
Among a total of 17,516 AA DDK transplant recipients, 3303 were in KDPI 0%-20% (AA donor = 239; non-AA donor = 3064), 5821 in KDPI 21%-50% (AA donor = 1414; non-AA donor = 4407), 6364 in KDPI 51%-85% (AA donor = 1619; non-AA donor = 4745), and 2028 in KDPI 86%-100% (AA donor = 932; non-AA donor = 1096) groups. Adjusted overall graft, death-censored graft, and patient survival were similar between AA recipients of AA vs non-AA donor kidneys across all KDPI groups.
Our study showed similar outcomes for transplanting AA vs non-AA deceased-donor kidneys into AA recipients despite the generally observed inferior outcomes associated with AA donor kidney transplantation.
与非非裔美国(AA)供体肾脏相比,移植 AA 供体肾脏通常与较差的结果相关。目前尚不清楚当 AA 供体肾脏移植到 AA 受者时,与 AA 供体肾脏相关的增强遗传风险是否会被有利的免疫匹配所平衡。我们旨在比较按肾供体概况指数(KDPI)分层的 AA 与非 AA 死亡供体肾脏(DDK)在移植到 AA 受者后的结果。
我们使用器官获取与移植网络/联合器官共享网络数据库,确定了 2000 年至 2015 年间接受围手术期诱导后使用钙调神经磷酸酶抑制剂/霉酚酸酯维持治疗的 AA DDK 受者。这些患者分为 4 个 KDPI 组(0%-20%、21%-50%、51%-85%和 86%-100%)。在每个 KDPI 类别中,使用多变量 Cox 模型比较 AA 受者接受来自 AA 与非 AA 供体的肾脏的长期移植物和患者结局。
在总共 17516 名 AA DDK 移植受者中,3303 名处于 KDPI 0%-20%(AA 供体=239;非 AA 供体=3064),5821 名处于 KDPI 21%-50%(AA 供体=1414;非 AA 供体=4407),6364 名处于 KDPI 51%-85%(AA 供体=1619;非 AA 供体=4745),2028 名处于 KDPI 86%-100%(AA 供体=932;非 AA 供体=1096)组。在所有 KDPI 组中,AA 受者接受 AA 与非 AA 供体肾脏的总体移植物、死亡风险调整移植物和患者存活率相似。
尽管与 AA 供体肾脏移植相关的结果通常较差,但我们的研究显示,将 AA 与非 AA 死亡供体肾脏移植到 AA 受者中的结果相似。